Although T2,N0,M0 esophageal adenocarcinoma is grouped with other locoregional disease by NCCN, no consensus exists about how it should be treated. One of the inherent complexities of treating T2,N0,M0 esophageal adenocarcinoma is the inaccuracy of the clinical staging.

The NCCN Clinical Practice Guidelines in Oncology for Gastric Cancer provide evidence and consensus based recommendations for a multidisciplinary approach for the management of patients with gastric cancer.

This webinar series is designed to provide an in-depth analysis of the evidence and clinical decision-making that led to the development of the NCCN Guidelines® for Colorectal, Hepatocellular, Pancreatic, and Gastric/Esophageal Cancers.

This webinar series is designed to provide an in-depth analysis of the evidence and clinical decision-making that led to the development of the NCCN Guidelines® for Colorectal, Hepatocellular, Pancreatic, and Gastric/Esophageal Cancers.

This congress is a full-day educational program designed to provide an in-depth analysis of the evidence and clinical decision-making that led to the development of the NCCN Guidelines® for Gastrointestinal Cancers.